Madrid

• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)
• First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome ( … Recruiting
  2025-523101-15-00 1 2026-02-16 Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysp
• A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting
  2024-516966-12-00 4 2026-02-13 Alzheimer’s disease
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A phase 2, randomized, double-blind study of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease. Recruiting
  2025-522146-40-00 4 2026-02-12 Late-onset Pompe disease.
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Clinical trial in multiple hospitals to explore new ways to diagnose and monitor tuberculosis treatment Recruiting
  2025-522235-34-00 6 2026-02-11 Bacterial pneumonia patients
• Phase 2 Study of INCB123667 in Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting
  2025-521513-14-00 4 2026-02-10 Ovarian Cancer
• C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors. Recruiting
  2025-521729-33-00 1 2026-02-10 advanced solid tumors
• A study to assess the safety, tolerability, pharmacokinetic, pharmacodynamic, immunogenicity and antitumour activity of IPN60300 in adults w … Recruiting
  2025-522139-33-00 7 2026-02-10 Advanced or metastatic solid tumours
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat … Recruiting
  2025-521873-15-00 9 2026-02-09 Metastatic hormone-sensitive prostate cancer
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• To Study the Effect of Inavolisib in Combination with Fulvestrant in Participants with Breast Cancer Recruiting
  2025-522805-39-00 4 2026-02-06 Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou … Recruiting
  2025-520771-59-00 4 2026-02-03 Atopic Dermatitis
• Finding treatments to slow the progression of chronic kidney disease Recruiting
  2024-520253-21-00 5 2026-02-02 Chronic Kidney Disease
• RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE … Recruiting
  2025-521802-17-00 5 2026-01-30 Erosive/inflammatory osteoarthritis of the hands
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A Phase 1 Study for ZW251 in Participants with Solid Tumors. Recruiting
  2025-523088-39-00 1 2026-01-28 Advanced Solid Tumors
• Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS Recruiting
  2025-520688-42-00 4 2026-01-27 Amyotrophic Lateral Sclerosis (ALS)
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors

Showing 745–768 of 3,550 trials